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A B S T R A C T
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
To assess the benefits and harms of drug-eluting stents versus bare-metal stents in participants with stable ischaemic heart disease.
B A C K G R O U N D
Description of the condition
Cardiovascular disease, in which ischaemic heart disease is the
largest component, is considered to be the number one cause
of death globally (Lloyd-Jones 2010; Nichols 2014; Rosamond
2008). According to theWorld Health Organization (WHO), 7.4
million people died from ischaemic heart disease in 2012, repre-
senting 15% of all global deaths (WHO 2015). Ischaemic heart
disease remains increasingly prevalent and costly to treat due to an
increase in life expectancy and a decrease in death rates (Cooper
2000; Schmidt 2012).
Ischaemic heart disease has different underlying mechanisms:
1. atherosclerotic plaque-related obstruction of the coronary
arteries;
2. focal or diffuse spasms of normal or plaque-diseased arteries;
3. microvascular dysfunction; and
4. left ventricular dysfunction caused by acute myocardial
necrosis or ischaemic cardiomyopathy (Montalescot 2013).
Ischaemic heart disease is generally divided into acute coronary
syndrome (ACS) and stable ischaemic heart disease (Roffi 2016).
Acute coronary syndrome has three different forms:
1. chest pain during rest (unstable angina pectoris);
2. acute non-ST-segment elevation myocardial infarction
(NSTEMI); and
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3. acute ST-segment elevation myocardial infarction (STEMI)
(Roffi 2016). The symptom of chest pain (angina) is usually
because of the blockage of a great coronary artery resulting in
ischaemia of the myocardium.
Episodes of reversible myocardial demand/supply mismatch, re-
lated to ischaemia or hypoxia (a condition where the tissue of the
heart is deprived of adequate oxygen supply) of the heart muscle
commonly associated with transient chest discomfort, define sta-
ble ischaemic heart disease. The symptoms are usually precipitated
by, for example, walking, emotion, or stress with none to minimal
symptoms at rest and symptom relief with the administration of
sublingual nitroglycerin (Montalescot 2013).
Historically, the degree of luminal stenosis (abnormal narrowing
of the lumen of the vessel) and the number of coronary arteries
involved (single-vessel disease, double-vessel disease, or triple-ves-
sel disease) have defined the severity of ischaemic heart disease
(Ringqvist 1983). More recently, researchers have developed more
comprehensive scorings systems (Farooq 2013; Gensini 1983;
Seizer 1982; Sianos 2005). Coronary angiography score and two
additional scores, i.e. vascular scoring and stenosis scoring, deter-
mine the Gensini score (Gensini 1983). The SYNTAX score II is
used to improve the decision-making in choosing between percu-
taneous coronary intervention (PCI) and coronary artery bypass
grafting (CABG) for a long-term, individualised risk assessment
in patients with complex ischaemic heart disease. The SYNTAX
score II combines the anatomical-based SYNTAX score (Sianos
2005), as well as seven clinical variables (creatinine clearance, pe-
ripheral vascular disease, unprotected left main coronary disease,
gender, chronic obstructive pulmonary disease, age, and left ven-
tricular ejection fraction) (Farooq 2013; Sianos 2005).
Description of the intervention
PCI is performed by inserting an access sheath into a peripheral
artery (most often the femoral artery or the radial artery); a catheter
is advanced, under X-ray screening, through the blood vessels to
the aortic root, at the origin of the coronary arteries. Other tools
such as balloons and stents can then be advanced down the artery,
over a guide wire, to the location of the narrowing or blockage (
Cantor 2005;Hamon2009). AndreasRolandGrüntzig performed
the first PCI in 1977 (Grüntzig 1978). PCI has since then evolved
to become one of the cornerstones in the treatment of ischaemic
heart disease.
PCI in patients with stable ischaemic heart disease is often per-
formed as an elective treatment. This is performed in the following
patients:
1. those where coronary artery bypass grafting is not
indicated; and
2. those who due to severe angina (Canadian Cardiovascular
Society Grade III to IV) are dissatisfied with their quality of life
(Montalescot 2013).
The first PCI was performed by inflating a balloon at the blockage
of the coronary artery to dilate the artery (’balloon angioplasty’)
(Grüntzig 1978; Grüntzig 1979). The healing properties of the
treatment seem tobe related to the PCI expanding the outer diame-
ter of the blocked coronary artery and not by decompression of the
arterial plaque (Düber 1986). Balloon angioplasty however gen-
erally did not seem to achieve a long-lasting result, with restenosis
occurring over time (Puel 1988). In an attempt to keep the lumen
open for longer, the next developmentwas a small metallic scaffold
called a “stent”. These tubular devices are expanded over a bal-
loon and press against the walls of the artery to keep it open (Puel
1988). These first devices were subsequently termed “bare-metal
stents” (after the later introduction of “drug-eluting stents”) and
improved outcomes over balloon angioplasty, but still had high
rates of restenosis over time (Erbel 1998; Fischman 1994; Macaya
1996; Puel 1988; Serruys 1994; Serruys 1998).
Newer drug-eluting stents have decreased strut thickness and are
meant to have improved flexibility/deliverability, enhanced poly-
mer biocompatibility/drug-eluting profiles, and superior re-en-
dothelialisation kinetics (Serruys 2010; Stone 2010). They typi-
cally use everolimus or zotarolimus as their antiproliferative drug
(Serruys 2010; Stone 2010).
The polymer-coating of the drug-eluting stents has been linked
with adverse events, such as stent thrombosis (Chen 2015). There-
fore, both drug-eluting stents with a biodegradable polymer as well
as polymer-free drug-eluting stents have been developed. Poly-
mer-free drug-eluting stents use the same antiproliferative drugs
(such as paclitaxel or sirolimus) as the polymer drug-eluting stents
(Abizaid 2010; Chen 2015).
In an attempt to further reduce the risk of restenosis, bioresorbable
(also called biodegradable) stents were developed. The principal
components of the bioresorbable stent are the same as the drug-
eluting stents; however, in most cases, a polylactic acid mesh re-
places themetal mesh (Haude 2013; Puricel 2015). The polylactic
acid mesh is broken down and removed over time (Tamai 2000).
The same types of drugs (everolimus, paclitaxel, sirolimus) used in
drug-eluting stents along with biolimus are used in bioresorbable
stents (Haude 2013; Haude 2016; Puricel 2015).
Bare-metal stents, drug-eluting stents, and bioresorbable stents are
used in modern PCIs, with drug-eluting stents generally being the
first choice (Windecker 2014). Guidelines recommend that acute
coronary syndrome patients receive 12months of antiplatelet ther-
apy (aspirin and a P2Y12 receptor blocker) regardless of whether
PCI is performed (Windecker 2014). The minimum length of
duration for the implant of the bare-metal stents and drug-eluting
stents is recommended to be one month and six months, respec-
tively (Windecker 2014).
Adverse events associated with PCI include death, coronary artery
complications (such as perforation of the artery, distal embolisa-
tion (passage of an intravascular mass, which is capable of clogging
capillaries), or stent thrombosis), myocardial infarction (type four
myocardial infarction) (Thygesen 2012), vascular complications
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(such as bleeding or infection at the access site, retroperitoneal
bleeding, or atheroembolism), stroke, and acute kidney failure
(Baim 1996; Cantor 1998; Stankovic 2004).
How the intervention might work
PCI aims to decrease the stenosis of the coronary artery resulting
in increased blood flow to the myocardium of the heart, which is
thought to limit ischaemia andpotentially reinfarction.Drug-elut-
ing stents may be more beneficial than bare-metal stents because
they release antiproliferative drugs, which cause less neointimal
growth (Holmes 2004; Stone 2004; Serruys 2010; Stone 2010).
The new bioresorbable stents as well as the polymer-free drug-
eluting stents may be even more beneficial since they remove ma-
terial that has been associated with adverse events (Abizaid 2010;
Chen 2015; Haude 2013; Puricel 2015).
Why it is important to do this review
The prevalence of ischaemic heart disease is considerable and
causes one third of all deaths in patients over the age of 35 years
(Lloyd-Jones 2010; Nichols 2014; Rosamond 2008). Beneficial
treatments can therefore alleviate a considerable disease burden
and healthcare cost.
Several systematic reviews and meta-analysis have previously as-
sessed the effects of PCI for stable ischaemic heart disease. How-
ever, none of these reviews have exclusively assessed people with
stable ischaemic heart disease.
Former evidence on drug-eluting stents versus bare-
metal stents for stable ischaemic heart disease
A2010 Cochrane Review compared drug-eluting stents with bare-
metal stents in participants with both acute coronary syndrome
and stable ischaemic heart disease (Greenhalgh 2010). It found
no significant when comparing drug-eluting stents and bare-metal
stents on mortality, incidence of acute myocardial infarction, and
thrombosis. However, the review showed indications of beneficial
effect of drug-eluting stents on target lesion revascularisation, tar-
get vessel revascularisation, and a composite outcome of cardiac
events compared with bare-metal stents.
Three meta-analyses have assessed the effects of drug-eluting
stents versus bare-metal stents (Kastrati 2007; Roukoz 2009;
Stettler 2007).Of the threemeta-analyses, two compared sirolimus
stents and paclitaxcel stents with bare-metal stents (Roukoz 2009;
Stettler 2007), while one compared only sirolimus stents with
bare-metal stents (Kastrati 2007). All three meta-analyses found
no effect onmortality of sirolimus and paclitaxcel stents compared
with bare-metal stents. Stettler 2007 found a beneficial effect in
favour of the drug-eluting stents using sirolimus on myocardial
infarction, it found no effect for drug-eluting stents using pacli-
taxel. Kastrati 2007 and Roukoz 2009 found no difference be-
tween drug-eluting stents versus bare metal stents on myocardial
infarction. All three meta-analyses found a beneficial effect favour-
ing drug-eluting stents on target vessel revascularisation (Kastrati
2007; Roukoz 2009; Stettler 2007).
Current guidelines on drug-eluting stents versus bare-
metal stents for stable ischaemic heart disease
TheAmericanCollege of Cardiology Foundation/AmericanHeart
Association/Society forCardiovascular Angiography and Interven-
tions guideline (ACCF/AHA/SCAI) (Levine 2011) have assessed
the effects of drug-eluting stents versus bare-metal stents.
The ACCF/AHA/SCAI recommend drug-eluting stents as an al-
ternative to bare-metal stents to prevent restenosis in cases where
there is an increased risk of restenosis, and the patient is likely to
be able to tolerate and comply with prolonged dual antiplatelet
therapy. The clinical situations associated with increased risk of
restenosis are left main disease, small vessels, in-stent restenosis,
bifurcations, diabetes, long lesions, multiple lesions, and saphe-
nous vein grafts (Levine 2011). The guideline also states that bare-
metal stents should be used in patients with a high risk of bleeding,
inability to comply with one year of dual antiplatelet therapy, or
anticipated invasive or surgical procedures in the next year.
The National Institute for Health and Care Excellence (NICE)
has assessed the effects of drug-eluting stents (NICE 2008). NICE
recommends drug-eluting stents in cases where the target artery
for treatment has less than a 3 mm calibre or the lesion is longer
than 15 mm, and the price difference between drug-eluting stents
and bare-metal stents is no more than £300 (GBP).
Problems with major adverse cardiac events (MACE)
as an outcome
In recent years, two major reports have described and analysed
several issues regarding the cardiac composite outcome MACE
(Cutlip 2007; Kip 2008). The main issues regarding MACE con-
cern the variability and lack of consistency in which outcomes are
included in the composite outcome (Cutlip 2007; Kip 2008). This
may lead to misleading conclusions. The main issue with MACE
in this particular review is the problem with using target vessel
revascularisation or target lesion revascularisation as components
of MACE. There are several reasons for this being problematic.
First, it is important to remember that the decision of whether or
not target vessel revascularisation will be performed is based on
a subjective opinion. Since both treatment providers and partic-
ipants will presumably not be blinded to treatment allocation in
the included trials, target vessel revascularisation and target lesion
revascularisation may introduce bias. Secondly, using a compos-
ite outcome consisting of safety endpoints (death and myocardial
infarction) and outcomes presumed to be a measure of procedu-
ral effectiveness (target vessel revascularisation and target lesion
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revascularisation) could lead to erroneous conclusions (Kip 2008).
Therefore, we have decided not to use MACE as a composite out-
come. Instead, we will use a composite cardiovascular outcome
consisting of cardiovascular mortality and myocardial infarction.
This review is an update of a 2010 Cochrane Review that has now
been divided into two reviews (Greenhalgh 2010): a review in-
cluding ACS participants and a review including stable ischaemic
heart disease participants. To our knowledge, no former review has
assessed the effect of drug-eluting stents versus bare-metal stents
only in patients with stable ischaemic heart disease. Additionally,
no review assessing the effect of drug-eluting stents versus bare-
metal stents in patients with ischaemic heart disease is up-to-date
with the latest trials. The present review will also be the first to do
the following:
1. take full account of the risk of systematic errors (’bias’),
design errors, and risks of random errors (’play of chance’)
(Higgins 2011; Jakobsen 2014; Keus 2010; Thorlund 2011;
Wetterslev 2008);
2. include trials irrespective of outcome, follow-up duration,
and number of participants;
3. assess outcomes at several time points and take into account
the variability of the follow-up period; and
4. include all types of drug-eluting stents, including polymer-
free stents and bioresorbable stents.
O B J E C T I V E S
To assess the benefits and harms of drug-eluting stents versus bare-
metal stents in participants with stable ischaemic heart disease.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We will search for randomised clinical trials (both individual and
cluster-randomised trials) irrespective of publication type, publi-
cation status, publication date, and language.
Types of participants
We will include participants of any age with a diagnosis of stable
ischaemic heart disease (according to the definition of the trialists).
If we identify trials where only a subset of participants are eligible
for our review, we will only include these data if the trialists report
separate valid data for the specific participants relevant for our
review according to our predefined inclusion and exclusion criteria
or we are able to obtain such data from the authors.
Types of interventions
We will include any type of drug-eluting stents, including biore-
sorbable stents and polymer-free drug-eluting stents.
We will accept any type of medical therapy as a co-intervention to
percutaneous coronary intervention (PCI).
We will include any type of bare-metal stent as a control interven-
tion.
Types of outcome measures
Primary outcomes
1. All-cause mortality.
2. Serious adverse events defined as any untoward medical
occurrence that resulted in death, was life-threatening, was
persistent, or led to significant disability; prolonged
hospitalisation; or any medical event that had jeopardised the
participant or required intervention to prevent it (ICH-GCP
1997).
3. Major cardiovascular event defined as a composite outcome
consisting of cardiovascular mortality and myocardial infarction.
4. Quality of life measured on any valid scale, such as the
Seattle Angina Questionnaire or 36-Item Short Form Survey
(SF-36) (Ware 1992; Wyrwich 2004)
Secondary outcomes
1. Cardiovascular mortality (defined by the trialists).
2. Myocardial infarction (defined by the trialists).
3. Angina on a continuous scale, such as ’angina stability’ and
’angina frequency’ used in the Seattle Angina Questionnaire
(Wyrwich 2004).
Exploratory outcomes
1. Stent thrombosis.
2. Target vessel revascularisation (defined by the trialists). In
general, target vessel revascularisation is any repeat percutaneous
intervention or surgical bypass of any segment of the target vessel
(Hicks 2010).
We will narratively report adverse events, presenting them in a
table.
We will conduct meta-analyses when possible of all dichotomous
and continuous outcomes at the following two time points:
• outcomes assessed at maximal follow-up (this will be the
time point of primary interest); and
• outcomes assessed at three months or earlier.
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Search methods for identification of studies
Electronic searches
Wewill identify trials through systematic searches of the following
bibliographic databases:
• the Cochrane Central Register of Controlled Trials
(CENTRAL) in the Cochrane Library;
• MEDLINE Ovid;
• Embase Ovid;
• LILACS (Latin American and Caribbean Health Science
Information Database) (BIREME);
• Science Citation Index Expanded (Thomson Reuters Web
of Science);
• BIOSIS Citation Index (Thomson Reuters Web of Science).
The preliminary search strategy for MEDLINE Ovid will be
adapted for use in the other databases (Appendix 1). TheCochrane
sensitivity-maximising RCT filter, Lefebvre 2011, will be applied
to MEDLINE Ovid, and adaptations of it will be applied to the
other databases, except CENTRAL.
We will also conduct a search of the US National Insti-
tutes of Health Ongoing Trials Register ClinicalTrials.gov (
www.clinicaltrials.gov) and the World Health Organization
International Clinical Trials Registry Platform (ICTRP) (
www.apps.who.int/trialsearch). We will also search Google
Scholar manually for trials not found in the preliminary search
(Lefebvre 2011).
We will search all databases from their inception to the present,
and we will impose no restriction on language of publication. If we
identify any papers in a language not known by the author group,
we will seek professional assistance, which we will acknowledge in
the Acknowledgements section.
Searching other resources
We will identify additional trials from the reference lists of review
articles and identified trials.
Data collection and analysis
Wewill perform the review following the recommendations of the
Cochrane Handbook for Systematic Reviews of Interventions (Higgins
2011). We will perform the analyses using Review Manager 5
(RevMan 2014), Stata 14 (Stata 2015), and trial sequential analysis
(CTU 2011).
Selection of studies
Two review authors (EEN and JF) will independently screen titles
and abstracts of all of the potentially eligible trials for inclusion.
We will code all of these studies as ’retrieve’ (eligible or potentially
eligible/unclear) or ’do not retrieve’. If there are any disagreements,
we will ask a third author to arbitrate (JCJ). We will retrieve the
full-text trial reports/publications, and two review authors will
independently screen the full texts and identify trials for inclusion.
We will report reasons for exclusion of the ineligible studies. We
will resolve any disagreement through discussion, or if required,
we will consult a third person (JCJ). We will identify and exclude
duplicates and collatemultiple reports of the same trial so that each
trial, rather than each report, is the unit of interest in the review.
Wewill record the selection process in sufficient detail to complete
a PRISMA flow diagram and ’Characteristics of excluded studies’
tables.
Data extraction and management
We will use a data collection form, which we have piloted on
at least one trial in the review, to collect trial characteristics and
outcome data. Two review authors (JF and EEN) will extract trial
characteristics from included trials. We will extract the following
trial characteristics.
1. Methods: duration of the trial, details of any ’run-in’
period, and date of publication.
2. Participants: number randomised, number analysed, mean
age, sex, inclusion criteria, and exclusion criteria.
3. Interventions: intervention, comparison, concomitant
medications, and excluded medications.
4. Outcomes: primary and secondary outcomes specified and
collected and time points reported.
5. Notes: trial funding and notable conflicts of interest of the
trial authors.
Two review authors (EEN and JF) will independently extract out-
come data from included studies. We will resolve disagreements
by consensus or by involving a third person (JCJ). One review
author (EEN) will transfer data into the Review Manager 5 file
(RevMan 2014). We will double-check that data is entered cor-
rectly by comparing the data presented in the systematic review
with the study reports. A second review author will spot-check
study characteristics for accuracy against the trial report.
Assessment of risk of bias in included studies
We will use the instructions given in the Cochrane Handbook for
Systematic Reviews of Interventions in our evaluation of themethod-
ology and the risk of bias of the included trials (Higgins 2011).
Two review authors will independently assess the included tri-
als. We will evaluate the risk of bias in random sequence gener-
ation; allocation sequence concealment; blinding of participants
and personnel; blinding of outcome assessment; incomplete out-
come data; selective outcome reporting, including industry fund-
ing; and other bias sources. This is done because these compo-
nents enable classification of randomised trials with a bias assess-
ment of low, high, or unclear. The latter trials overestimate ben-
efits and underestimate harms (Gluud 2006; Hróbjartsson 2012;
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Hróbjartsson 2013; Kjaergard 2001; Lundh 2012; Moher 1998;
Savovi 2012; Schulz 1995; Wood 2008). For additional details
on how we will assess risk of bias, see Appendix 2.
Assessment of bias in conducting the systematic
review
We will conduct the review according to this published protocol
and report any deviations from it in the ’Differences between pro-
tocol and review’ section of the review.
Measures of treatment effect
Dichotomous outcomes
We will calculate risk ratios (RR) with 95% confidence intervals
(CIs), as well as the TSA-adjusted CI for dichotomous outcomes.
Continuous outcomes
We will include both end scores and change scores in our analyses.
We will use end scores in the analyses if both are reported. We will
calculate the mean differences (MDs) and the standardised mean
differences (SMDs) with 95% CIs for continuous outcomes. We
will use the standardised mean difference when the trials all assess
the same outcome but measure it in a variety of ways, e.g. with
different scales (Higgins 2011).
Dealing with missing data
Wewill contact investigators or study sponsors to obtain any miss-
ing data.
Dichotomous outcomes
Wewill not imputemissing values for any outcomes in our primary
analysis. In two of our sensitivity analyses, we will impute data
(see Sensitivity analysis).
Continuous outcomes
We will not impute missing values for any outcomes in our pri-
mary analysis. In our sensitivity analysis for dichotomous and con-
tinuous outcomes, we will impute data (see Sensitivity analysis).
If studies do not report standard deviations (SD), we will calculate
them using data from the trial if possible.
Assessment of heterogeneity
We will primarily investigate forest plots to visually assess any sign
of heterogeneity. We will secondly assess the presence of statisti-
cal heterogeneity by Chi² test (threshold P < 0.10) and measure
the quantities of heterogeneity by the I² statistic (Higgins 2002;
Higgins 2003). We will follow the recommendations for thresh-
olds in the Cochrane Handbook for Systematic Reviews of Interven-
tions (Higgins 2011):
• 0% to 40%: might not be important;
• 30% to 60%: may represent moderate heterogeneity;
• 50% to 90%: may represent substantial heterogeneity; and
• 75% to 100%: may represent considerable heterogeneity.
We will investigate possible heterogeneity through subgroup anal-
yses. Ultimately, we may decide that we should avoid a meta-anal-
ysis (Higgins 2011).
Assessment of reporting biases
We will assess publication bias and other reporting biases by visual
inspection of funnel plots for primary outcomes if we include at
least 10 trials (Higgins 2011). Using the asymmetry of the funnel
plot, we will assess the risk of bias.
For dichotomous outcomes, we will test asymmetry with the Har-
bord test, Harbord 2006, if τ ² is less than 0.1 and with the Rücker
test, Rücker 2008, if τ ² is more than 0.1.
For continuous outcomes, we will use the regression asymmetry
test (Egger 1997).
Data synthesis
Meta-analysis
We will undertake this systematic review according to the recom-
mendations stated in the Cochrane Handbook for Systematic Re-
views of Interventions (Higgins 2011), according to Keus 2010,
and according to the eight-step assessment suggested by Jakobsen
2014. We will use the statistical software Review Manager 5, pro-
vided by Cochrane, to meta-analyse data (RevMan 2014).
We will use Stata, Stata 2015, in case of zero-event trials where
ReviewManger 5’s zero-event handling (replacing zero with a con-
stant of 0.5) is not sufficient, e.g. in cases with a skewed number of
participants between groups, which we will handle with reciprocal
zero-event handling according to Sweeting 2004, and in case we
need to undertake meta-regression (post hoc).
We will use trial sequential analysis (TSA) to assess and control
the risk of random error. If the review does not reach the required
information size, we will present TSA-adjusted confidence inter-
vals to account for the lack of information.
If the included studies report both end scores and change-from-
baseline scores, meta-analysing continuous outcomes, we will use
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end scores. If they report only change, we will analyse the results
together with end scores (Higgins 2011a).
We will include all studies in our initial analyses and conduct
a sensitivity analysis of studies at low risk of bias. If the results
are similar, we will base our primary conclusions on the overall
analysis. If they differ, we will base our primary conclusions on
studies at low risk of bias.
However, we do not expect to identify any trials performing ade-
quate blinding of participants and personnel because of the nature
of the PCI procedure. Under these circumstances, we will instead
conduct a sensitivity analysis of the results at low risk of bias in all
bias risk domains except ’blinding of participants and personnel’.
If the results differ from the overall analysis, we will base our pri-
mary conclusions on the results of the analyses of the primary out-
comes with low risk of bias in all bias risk domains except ’blind-
ing of participants and personnel’ and the trial sequential analysis-
adjusted CIs (see below). We will discuss in the final review the
limitations of the expected lack of ’blinding of participants and
personnel’ for conclusions (Hróbjartsson 2014; Pocock 2015).
Trial sequential analysis
Cumulative meta-analyses are at risk of producing random er-
rors due to sparse data and multiple testing of accumulating data
(Brok 2008; Brok 2009; Higgins 2011a; Pogue 1997; Thorlund
2009; Wetterslev 2008); therefore, trial sequential analysis (TSA)
can be applied to control this risk (CTU 2011; www.ctu.dk/tsa)
(Thorlund 2011). The required information size (that is the num-
ber of participants needed in a meta-analysis to detect or reject a
certain intervention effect) can be calculated in order to minimise
random errors (Wetterslev 2008; Wetterslev 2009). The required
information size takes into account the event proportion in the
control group, the assumption of a plausible relative risk reduc-
tion, and the heterogeneity of the meta-analysis (Turner 2013;
Wetterslev 2008; Wetterslev 2009). TSA enables testing for sig-
nificance each time a meta-analysis includes a new trial. On the
basis of the required information size, trial sequential monitoring
boundaries can be constructed. This enables one to determine the
statistical inference concerning cumulative meta-analysis that has
not yet reached the required information size (Wetterslev 2008).
Firm evidence for benefit or harms may be established if the trial
sequential monitoring boundary is crossed before reaching the re-
quired information size, in which case further trials may turn out
to be superfluous. In contrast, if the boundaries for benefit or harm
are not surpassed, one may conclude that it is necessary to con-
tinue with further trials before a certain intervention effect can be
detected or rejected. Firm evidence for lack of the postulated inter-
vention effect can also be assessed with TSA. This occurs when the
cumulative Z-score crosses the trial sequential monitoring bound-
aries for futility.
To control the risks of random errors, we have used relatively con-
servative estimations of the anticipated intervention effect esti-
mates (Jakobsen 2014). Large anticipated intervention effects lead
to small required information sizes, and the thresholds for signifi-
cance will be less strict after the information size has been reached
(Jakobsen 2014).
We will analyse all primary and secondary outcomes with TSA.
We will use the following assumptions.
Primary outcomes
We will estimate the diversity-adjusted required information size
based on the proportion of patients with an outcome in the control
group (Wetterslev 2009). We will use an alpha of 2% (Jakobsen
2014), a beta of 20%, and the diversity suggested by the trials in
the meta-analysis (Jakobsen 2014).
As anticipated intervention effects for the primary outcomes in
the trial sequential analysis, we will use the following relative risk
reductions or increases because they seem to be the maximum re-
alistic intervention effect estimates based on former studies, trials,
and meta-analyses.
1. All-cause mortality: relative risk reduction or increase of
10% (Holmes 2004; Kastrati 2007; Roukoz 2009; Stettler 2007).
2. Serious adverse events: relative risk reduction or increase of
10%.
3. Composite event outcome (cardiovascular mortality and
acute myocardial infarction): relative risk reduction or increase of
10% (Holmes 2004; Kastrati 2007; Roukoz 2009; Stone 2004;
Stettler 2007).
4. Quality of life: we will use the observed SD, a clinically
relevant mean difference equal to SD/2.
Secondary outcomes
We will estimate the diversity-adjusted required information size
based on the proportion of participants with an outcome in the
control group (Wetterslev 2009). We will use an alpha of 2.5%
(Jakobsen 2014), a beta of 20%, and the diversity suggested by
the trials in the meta-analysis (Jakobsen 2014).
As anticipated intervention effects for the secondary outcomes in
the trial sequential analysis, we will use the following relative risk
reductions or increases because they seem to be realistic interven-
tion effect estimates based on former studies, trials, and meta-
analyses as cited below.
• Angina (continuous outcome): we will use the observed
SD, a clinically relevant mean difference equal to SD/2.
Exploratory outcomes
• Stent thrombosis: relative risk reduction or increase of 10%.
• Target vessel revascularisation: relative risk reduction or
increase of 40% (Roukoz 2009; Stettler 2007).
As a supplementary trial sequential analysis, we will use the limit
of the confidence interval closest to zero effect as the anticipated
intervention effect for all trial sequential analyses (Jakobsen 2014).
Assessment of significance
We will assess our intervention effects with both random-effects
meta-analyses, DerSimonian 1986, and fixed-effectmeta-analyses,
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Demets 1987, andwewill use themore conservative point estimate
of the two (Jakobsen 2014). The more conservative point estimate
is the estimate closest to zero effect. If the two estimates are equal,
we will use the estimate with the widest confidence interval. We
have four primary outcomes and will therefore consider a P value
less than 2% as significant (Jakobsen 2014). We will use the eight-
step procedure to assess if the thresholds for significance are crossed
or not (Jakobsen 2014).
We will present a table describing the types of serious adverse
events in each trial.
’Summary of findings’ tables
We will use the GRADE system to assess the quality of the
body of evidence associated with each of the primary and sec-
ondary outcomes in our review (Guyatt 2008), constructing ’Sum-
mary of findings’ (’SoF’) tables using the GRADEpro software (
www.gradepro.org). The GRADE approach appraises the qual-
ity of a body of evidence based on the extent to which one can
be confident that an estimate of effect or association reflects the
item being assessed. The quality measure of a body of evidence
considers within-study risk of bias, the directness of the evidence,
heterogeneity of the data, precision of effect estimates, and risk of
publication bias. We will include all studies in our analyses and
conduct a sensitivity analysis with studies at low risk of bias. If
we include no studies at low risk of bias studies, we will conduct
the sensitivity analysis with studies at low risk of bias in all other
domains than ’blinding of participants and personnel’. If the re-
sults are similar, we will base our primary ’SoF’ tables and primary
conclusions on the overall analysis. If they differ, we will base our
primary ’SoF’ and primary conclusions on studies with low risk of
bias or alternatively, studies with low risk of bias in all ’Risk of bias’
domains except ’blinding of participants and personnel’ (Gluud
2006; Kjaergard 2001; Lundh 2012; Moher 1998; Savovi 2012;
Schulz 1995; Wood 2008).
Subgroup analysis and investigation of heterogeneity
We plan to carry out the following subgroup analyses.
A) Type of drug-eluting stents used:
• paclitaxel-eluting stents;
• sirolimus-eluting stents;
• zotarolimus-eluting stents;
• everolimus-eluting stents;
• bioresorbable stents;
• polymer-free drug-eluting stents; and
• mixed drug-eluting stents.
B) Length of maximum follow up:
• less or equal to six months;
• between six months and 12 months;
• between one year and three years; and
• more than or equal to three years.
C) Participants with diabetes compared with participants without
diabetes.
D) Participants with high risk of bleeding (as defined by the trial-
ists) compared with participants without high risk of bleeding.
E) Age of participants:
• age 0 to 18;
• age 19 to 75; and
• age 76 or above.
F) Comparison of the effect of beta-blockers versus placebo or no
intervention between trials with different clinical trial registration
status:
• preregistration;
• postregistration; and
• no registration.
We will use the primary outcomes in our subgroup analyses.
We will use the formal test for subgroup interactions in Review
Manager 5 (RevMan 2014).
Sensitivity analysis
To assess the potential impact of bias, we will perform a sensitivity
analysis where we exclude trials with an overall high risk of bias.
As a secondary sensitivity analysis, we will only include trials with
low risk of bias in all domains except ’blinding of participants and
personnel’, as we do not expect to find any trials at low risk of bias
in this domain.
To assess the potential impact of themissing data for dichotomous
outcomes, we will perform the two following analyses.
1. ’Best-worst-case’ scenario: we will assume that all
participants lost to follow up in the experimental group survived,
had no serious adverse event, had no major cardiovascular event,
had no stent thrombosis, and had no target vessel
revascularisation. We will assume that they also had a beneficial
event with regard to quality of life and angina, defined as the
group mean plus both one and two standard deviations of the
group mean (Jakobsen 2014). We will assume that all of those
with missing outcomes in the control group died, had a serious
adverse event/s, had a major cardiovascular event, had stent
thrombosis, and had target vessel revascularisation. We will
assume that they also had a harmful event with regard to quality
of life and angina, defined as the group mean plus both one and
two standard deviations of the group mean (Jakobsen 2014).
2. ’Worst-best-case’ scenario: we will assume that all
participants lost to follow up in the experimental group died,
had a serious adverse event, had a major cardiovascular event,
had stent thrombosis, and had target vessel revascularisation. We
will assume that they also had a harmful event with regard to
quality of life and angina, defined as the group mean plus both
one and two standard deviations of the group mean (Jakobsen
2014). We will assume that all of those with missing outcomes in
the control group control group survived, had no serious adverse
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event, had no major cardiovascular event, had no stent
thrombosis, and had no target vessel revascularisation. We will
assume that they also had a beneficial event with regard to quality
of life and angina, defined as the group mean plus both one and
two standard deviations of the group mean (Jakobsen 2014).
We will present results from both scenarios.
To assess the potential impact of missing SDs for continuous out-
comes, we will perform the following sensitivity analyses.
• Where SDs are missing and not possible to calculate, we
will impute SDs from trials with similar populations and low risk
of bias.
• If we find no such trials, we will impute SDs from trials
with a similar population. As the final option, we will impute
SDs from all trials.
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A P P E N D I C E S
Appendix 1. Preliminary MEDLINE Ovid search strategy
1. Stents/
2. stent*.tw.
3. 1 or 2
4. drug elut*.tw.
5. Sirolimus/
6. sirolimus.tw.
7. rapamycin.tw.
8. paclitaxel.tw.
9. taxol.tw.
10. exp Immunosuppressive Agents/
11. coat* stent*.tw.
12. exp Taxoids/
13. taxane*.tw.
14. qp2.tw.
15. hexanoyltaxol.tw.
16. everolimus.tw.
17. abt-578.tw.
18. Tacrolimus/
19. Dactinomycin/
20. actinomycin.tw.
21. batimastat.tw.
22. exp Dexamethasone/
23. dexamethasone.tw.
24. exp Estradiol/
25. estradiol.tw.
26. praxel.tw.
27. paxene.tw.
28. onxol.tw.
29. anzatax.tw.
30. immunosuppress*.tw.
31. prograf*.tw.
32. meractinomycin.tw.
33. cosmegen.tw.
34. dactinomycin.tw.
35. millicorten.tw.
36. maxidex.tw.
37. decaspray.tw.
38. dexpak.tw.
39. dexasone.tw.
40. oradexon.tw.
41. hexadecadrol.tw.
42. decaject.tw.
43. hexadrol.tw.
44. decameth.tw.
45. methylfluorprednisolone.tw.
46. vivelle.tw.
47. oestradiol.tw.
48. estrace.tw.
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49. aerodiol.tw.
50. estraderm.tw.
51. ovocyclin.tw.
52. estramustin*.tw.
53. estracyt.tw.
54. emcyt.tw.
55. tacrolimus.tw.
56. taxoids.tw.
57. zotarolimus.tw.
58. umirolimus.tw.
59. biolimus.tw.
60. pimecrolimus.tw.
61. elidel.tw.
62. or/4-61
63. 3 and 62
64. eluting stent*.tw.
65. 63 or 64
66. exp Angioplasty, Balloon, Coronary/ or exp Percutaneous Coronary Intervention/
67. balloon angioplast*.tw.
68. (percutaneous adj6 coronary intervention*).tw.
69. PCI.tw.
70. (intervention* adj6 percutaneous coronary).tw.
71. (revascularization* adj6 percutaneous coronary).tw.
72. (angioplast* adj6 coronary).tw.
73. percutaneous coronary.tw.
74. ((transluminal or trans-luminal) adj6 coronary).tw.
75. or/66-74
76. exp Myocardial Ischemia/
77. ((myocardial or myocardium or subendocardial or transmural or cardiac or cardial or coronary or heart) adj2 (infarct* or postinfarct*
or hypoxi* or anoxi* or failure* or decompensation or insufficien*)).tw.
78. (heart disease* or coronary disease* or IHD or CIHD or CHD).tw.
79. (myocardial dysfunction or angina or stenocardia).tw.
80. ((ischemi* or ischaemi*) adj2 (myocardium or myocardial or heart or coronary or cardiac or cardial or subendocardial or cardiomy-
opath*)).tw.
81. ((artery occlusion* or artery disease* or arterioscleros* or atheroscleros*) adj2 coronary).tw.
82. or/76-81
83. Acute Coronary Syndrome/
84. exp Myocardial Infarction/
85. exp Coronary Thrombosis/
86. coronary thrombosis.tw.
87. acute coronary.tw.
88. exp Angina, Unstable/
89. myocardial infarct*. tw.
90. heart infarct*.tw.
91. acs.tw.
92. ami.tw.
93. (coronary adj3 syndrome*).tw.
94. acute angina.tw.
95. (unstable adj3 angina).tw.
96. unstable coronary.tw.
97. or/83-96
98. randomized controlled trial.pt.
99. controlled clinical trial.pt.
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100. randomized.ab.
101. placebo.ab.
102. drug therapy.fs.
103. randomly.ab.
104. trial.ab.
105. groups.ab.
106. or/98-105
107. exp animals/ not humans.sh.
108. 106 not 107
109. 65 or 75
110. 82 or 97
111. 108 and 109 and 110
Appendix 2. Details on assessment of risk of bias
We will classify each trial according to the domains below for each outcome result.
Random sequence generation
• Low risk: if sequence generation is achieved using a computer random number generator or a random numbers table. We will
also consider drawing lots, tossing a coin, shuffling cards, and throwing dice as adequate if an independent adjudicator performs these
methods.
• Unclear risk: if there is insufficient information to permit judgement of ’low risk’ or ’high risk’.
• High risk: if the allocation sequence is not randomised or only quasi-randomised.
Allocation sequence concealment
• Low risk: if the allocation of participants results from a central independent unit, on-site locked computer, identical-looking
numbered sealed opaque envelopes, drug bottles, or containers prepared by an independent investigator. There must be no risk of the
investigator knowing the sequence.
• Unclear risk: if there is insufficient information to permit judgement of ’low risk’ or ’high risk’.
• High risk: if the allocation sequence is known to the investigators who assigned participants.
Blinding of participants and personnel
• Low risk: if the participants and the personnel are blinded to treatment allocation and this is described.
• Unclear risk: if there is insufficient information to permit judgement of ’low risk’ or ’high risk’.
• High risk: if blinding of participants and personnel is not performed.
Blinding of outcome assessment
• Low risk: if the trial investigators performing the outcome assessments, analyses, and calculations are blinded to the intervention.
• Unclear risk: if there is insufficient information to permit judgement of ’low risk’ or ’high risk’.
• High risk: if blinding of outcome assessment is not performed.
Incomplete outcome data
• Low risk: (1) there are no dropouts or withdrawals for all outcomes, or (2) the numbers and reasons for the withdrawals and
dropouts for all outcomes are clearly stated, can be described as being similar in both groups, and the trial handles missing data
appropriately in intention-to-treat analysis using proper methodology, e.g. multiple imputations. As a general rule, we will judge the
trial as at low risk of bias due to incomplete outcome data if the number of dropouts is less than five per cent. However, the five per
cent cut off is not definitive.
• Unclear risk: if there is insufficient information to permit judgement of ’low risk’ or ’high risk’.
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• High risk: the pattern of dropouts can be described as being different in the two intervention groups or the trial uses improper
methodology in dealing with the missing data, e.g. last observation carried forward.
Selective outcome reporting
• Low risk: a protocol is published before or at the time the trial begins and the outcomes called for in the protocol are reported
on. If there is no protocol or the protocol is published after the trial begins, reporting of the primary outcomes will grant the trial a
grade of low risk of bias.
• Unclear risk: if there is no protocol and the primary outcomes are not reported on.
• High risk: if the outcomes that are called on in a protocol are not reported on.
Other bias risk
• Low risk of bias: the trial appears to be free of other components (for example, academic bias or for-profit bias) that could put it
at risk of bias.
• Unclear risk of bias: the trial may or may not be free of other components that could put it at risk of bias.
• High risk of bias: there are other factors in the trial that could put it at risk of bias (for example, authors have conducted trials on
the same topic, for-profit bias, etc).
Overall risk of bias
• Low risk of bias: we will classify the outcome as overall ’low’ risk of bias only if we classify all of the bias domains described in the
aforementioned text as low risk of bias.
• High risk of bias: we will classify the outcome result as ’high’ risk of bias if we classify any of the bias risk domains described in
the aforementioned text as ’unclear’ or ’high’ risk of bias.
We will grade each potential source of bias as high, low, or unclear and provide a quote from the study report together with a justification
for our judgment in the ’Risk of bias’ table. We will summarise the ’Risk of bias’ judgements across different studies for each of the
domains listed. Where information on risk of bias relates to unpublished data or correspondence with a trialist, we will note this in the
’Risk of bias’ table.
When considering treatment effects, we will take into account the risk of bias for the studies that contribute to that outcome.
Appendix 3. Glossary
Ischaemic: reduced blood supply to an organ.
Angina pectoris: medical term for chest pain or discomfort due to ischaemic heart disease.
ST: ST is short for the ST-segment, which is a specific segment of the printout when recording an electrocardiogram. It is used to
differentiate between ST and non-ST myocardial infarction.
Non-ST-elevation myocardial infarction: a kind of heart attack which does not show ST-segment elevation on an electrocardiogram.
ST-elevation myocardial infarction: a kind of heart attack which shows ST-segment elevation on an electrocardiogram.
Atherosclerosis: arterial wall-thickening due to build up of plaque.
Stent thrombosis: blockage of the stent by a blood clot.
Angiography: visualisation of the blood vessels typically by injection of contrast and using x-ray.
Myocardium: the muscle tissue of the heart.
Myocardial necrosis: death of the muscle tissue of the heart.
Restenosis: narrowing of a previously narrowed blood vessel due to a blood clot.
Biolimus: the trade name of the drug Umirolimus. The mechanism of action is believed to be anti proliferation of smooth muscle cells.
Myocardial ischaemia: reduced blood supply to the heart.
Cardiomyocyte necrosis: undesirable death of the cells of the heart.
Atheroembolism: embolism originating from an atherosclerotic plaque.
Retroperitoneal bleeding: bleeding behind the peritoneum, a membrane lining the abdominal cavity.
Luminal stenosis: narrowing of the lumen of the vessel.
Neointimal: scar tissue formed in a vessel after an injury.
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Revascularisation: removing the cause of the stenosed blood vessel, allowing blood flow to resume.
Sirolimus stent: a stent using the sirolimus drug, a drug used in stents with the aim of reducing restenosis.
Paclitaxcel stent: a stent using the paclitaxcel drug, a drug used in stents with the aim of reducing restenosis.
Bifurcation: when a blood vessel splits into two different blood vessels.
Saphenous vein grafts: when performing bypass surgery, one may use the saphenous vein (located in the leg) to bypass the occluded
vessel, ultimately reestablishing heart flow.
Bioresorbable stents: stents that are absorbed after initial placement with the intent of reducing restenosis.
Everolimus: a drug used in stents with the aim of reducing restenosis.
Zotarolimus: a drug used in stents with the aim of reducing restenosis
Paclitaxel: a drug used in stents with the aim of reducing restenosis
Polymer-free drug-eluting stents: a stent coated with a drug with the aim of reducing restenosis, but without the polymer coating that
normally binds the drug to the stent.
Ischaemic cardiomyopathy: a disease of the heart caused by the narrowing of the coronary arteries which supply blood to the heart.
Balloon angioplasty: using a balloon to open a narrowed vessel.
Re-endothelialisation: regrowth of endothelium after injury.
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